Abstract
This review highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings. Aspirin reduces one fourth of all major cardiovascular events but also increases major gastrointestinal bleeds by about half. As with other cardiovascular prevention strategies, the absolute benefit of aspirin is linearly related to the cardiovascular risk of the patient. The risk-benefit of aspirin can vary substantially in different settings: in secondary prevention, the benefits usually outweigh the excess of major bleeding complications. In primary prevention, it is not unusual that the number of vascular events avoided equals the number of major bleeds induced by aspirin. Finally, there is a growing body of evidence suggesting that aspirin may interfere with the early stages of cancer, metastasis and mortality. For all these reasons, in this article new developments in the field directed towards individualized risk assessment strategies are also discussed.
Keywords: Aspirin, prevention cardiovascular diseases, GI damage, proton pump inhibitors.
Current Pharmaceutical Design
Title:A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Volume: 21 Issue: 35
Author(s): Rubén Casado-Arroyo, Angel Lanas and Pedro Brugada
Affiliation:
Keywords: Aspirin, prevention cardiovascular diseases, GI damage, proton pump inhibitors.
Abstract: This review highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings. Aspirin reduces one fourth of all major cardiovascular events but also increases major gastrointestinal bleeds by about half. As with other cardiovascular prevention strategies, the absolute benefit of aspirin is linearly related to the cardiovascular risk of the patient. The risk-benefit of aspirin can vary substantially in different settings: in secondary prevention, the benefits usually outweigh the excess of major bleeding complications. In primary prevention, it is not unusual that the number of vascular events avoided equals the number of major bleeds induced by aspirin. Finally, there is a growing body of evidence suggesting that aspirin may interfere with the early stages of cancer, metastasis and mortality. For all these reasons, in this article new developments in the field directed towards individualized risk assessment strategies are also discussed.
Export Options
About this article
Cite this article as:
Casado-Arroyo Rubén, Lanas Angel and Brugada Pedro, A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150915110322
DOI https://dx.doi.org/10.2174/1381612821666150915110322 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Heart Transplantation in Biventricular Congenital Heart Disease: Indications, Techniques, and Outcomes
Current Cardiology Reviews Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews Nucleic Acid Sequence Based Amplification (NASBA) of Chlamydia pneumoniae Major Outer Membrane Protein (ompA) mRNA with Bioluminescent Detection
Combinatorial Chemistry & High Throughput Screening Macrophage Differentiation to Foam Cells
Current Pharmaceutical Design 3, 5-Diiodothyronine: Biological Actions and Therapeutic Perspectives
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hypertension and Aortic Stenosis: A Review
Current Hypertension Reviews Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Current Vascular Pharmacology Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot Topic:Modifying Cardiovascular Risk Factors: Newer Insights and Preventive Measures (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design A Review of Obesity and Body Fat Distribution and Its Relationship to Cardio-Metabolic Risk in Men and Women of Chinese Origin
Cardiovascular & Hematological Disorders-Drug Targets Role of Curcumin in Modulating Plasma PON1 Arylesterase Activity and Susceptibility to LDL Oxidation in Oxidatively Challenged Wistar Rats
Letters in Drug Design & Discovery Antioxidant Therapy Against Trypanosome Infections: A Review Update
Current Topics in Medicinal Chemistry